Drug Profile
Vulinacimab - Henlix Biotech
Alternative Names: HLX-06Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Henlix Biotech
- Developer Henlius Biopharmaceuticals
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factor receptor-2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Solid-tumours in China (Infusion, Injection)
- 28 Feb 2022 No recent reports of development identified for preclinical development in Solid-tumours in USA (Infusion, Injection)
- 28 Apr 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Taiwan (Infusion, Injection)